Lourdes Weltzien - Jan 31, 2023 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC (VIVO)

Role: Executive VP, Life Science
Signature: /s/ F. Mark Reuter, as Attorney-in-Fact for Lourdes G. Weltzien
Stock symbol: VIVO
Transactions as of: Jan 31, 2023
Transactions value $: -$556,986
Form type: 4
Date filed: 1/31/2023, 01:10 PM
Previous filing: Nov 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIVO	Common Stock	Award		+7.95K	+10.17%		86K	Jan 31, 2023	Direct	F1
transaction	VIVO	Common Stock	Disposed to Issuer		-86K	-100%		0	Jan 31, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIVO	Stock Option (Right to Buy)	Disposed to Issuer	-$143K	-10K	-100%	$14.34	0	Jan 31, 2023	Common Stock	10K	$19.66	Direct	F3
transaction	VIVO	Stock Option (Right to Buy)	Disposed to Issuer	-$49.3K	-2.5K	-100%	$19.70	0	Jan 31, 2023	Common Stock	2.5K	$14.30	Direct	F4
transaction	VIVO	Stock Option (Right to Buy)	Disposed to Issuer	-$188K	-12.1K	-100%	$15.52	0	Jan 31, 2023	Common Stock	12.1K	$18.48	Direct	F5
transaction	VIVO	Stock Option (Right to Buy)	Disposed to Issuer	-$176K	-11.7K	-100%	$15.12	0	Jan 31, 2023	Common Stock	11.7K	$18.88	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Lourdes Weltzien is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Represents 7,945 shares of the Issuer's common stock awarded to the Reporting Person upon the vesting of a portion of an award of performance stock units ("PSUs") in connection with the closing of the transactions contemplated by the Merger Agreement (as defined below).
F2	The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F3	The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4	The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F5	The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F6	The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.